BioNTech Reports €184.5 Million Profit in Third Quarter

German biotechnology company BioNTech announced its financial results for the third quarter of this year. The company recorded a net profit of €184.5 million in the period. In the same quarter last year, it had posted a net loss of €28.7 million. Thus, BioNTech swung from a loss to a profit compared with the same period a year earlier. This improvement in the company's quarterly performance was reflected in the net profit figure. BioNTech also upwardly revised its revenue expectation for 2026. The company raised its revenue forecast for that year to a range of €1.7 billion to €1.9 billion. The company's reported net profit and revised revenue expectation were the standout headlines in terms of financial statements and guidance. Not investment advice.

📊 EUR — Piyasa Yorumu

▲ up · 60%

BioNTech's announcement of a €184.5 million profit, which appears above expectations, could support risk appetite for the healthcare and biotechnology sectors. The positive perception of the profit may bring short-term buying to technology and healthcare-weighted indices, particularly in European equity markets. However, this company-specific result may remain limited in determining the broad market direction on its own amid global macroeconomic uncertainties. While its direct impact on Turkish markets is low, a moderate improvement in global risk appetite could provide limited support for BIST and TL assets.

RSI 14

—

MACD

—

24h Δ

0.00%

Canlı Grafikler